Research and Applications Progress of Lenalidomide for Myelofibrosis--Review.
10.7534/j.issn.1009-2137.2018.06.046
- Author:
Wen-Jing FAN
1
;
Tao WU
2
;
Jia-Wen CHEN
2
;
Hai BAI
3
Author Information
1. Department of Hematology, Center for Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730059, Gansu Province, China The Second Hospital of Lanzhou University, Lanzhou 730030, Gansu Proince, China.
2. Department of Hematology, Center for Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730059, Gansu Province, China.
3. Department of Hematology, Center for Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730059, Gansu Province, China E-mail: baihai98@tom.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Lenalidomide;
therapeutic use;
Prednisone;
Primary Myelofibrosis;
drug therapy;
Quality of Life;
Thalidomide
- From:
Journal of Experimental Hematology
2018;26(6):1854-1857
- CountryChina
- Language:Chinese
-
Abstract:
Myelofibrosis, a clonal stem-cell disorder which is difficult to cure, The treatment for most of patients is conservative treatment, but the treatment effect is not ideal. Lenalidomide as a novel immunomodulator in the treatment of blood diseases showed good results in recent years, Its studies have shown that lenalidomide in myelofibrosis also showed a certain effect. As companed with single drug lenalidomide, the thalidomide has a higher response rate, clinical symptoms improved significantly. Ruxolitinib, JAK2 inhibitor, combined with lenalidomide not only can improve the quality of life of patients, but also extend the survival of patients. In addition, lenalidomide combined with prednisone for the treatment of bone marrow fibrosis is more effective and more safe, lenalidomide can significantly improve the clinical symptoms of patients, especially anemia, and prednisone can reduce the hematologic toxicity of lenalidomids. The purpose of this review is to evaluate the efficacy and safety of lenalidomide in the treatment of myelofibrosis, and focuses on the newest clinical research and application progress of lenalidomide for myelofibrosis.
